138 related articles for article (PubMed ID: 37850604)
1. The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency?
Szymański P; Bossano Prescott EI; Weidinger F
Eur Heart J; 2024 Jan; 45(1):7-9. PubMed ID: 37850604
[No Abstract] [Full Text] [Related]
2. JUPITER, rosuvastatin, and the European Medicines Agency.
Ridker PM; Glynn RJ
Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436
[No Abstract] [Full Text] [Related]
3. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
[TBL] [Abstract][Full Text] [Related]
4. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
5. Medicines under additional monitoring in the European Union.
Manso G; Neira F; Ortega S; Martín Arias LH; Sainz M; Salgueiro E
Farm Hosp; 2019 Jan; 43(1):19-23. PubMed ID: 30624169
[TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
Mogielnicki M; Swieczkowski D; Bachorski W; Zuk G; Gilis-Malinowska N; Zarzeka A; Merks P; Gruchala M; Jaguszewski M
Cardiol J; 2016; 23(5):515-517. PubMed ID: 27723064
[No Abstract] [Full Text] [Related]
7. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
8. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
9. For the European Medicines Agency, a decade of challenges.
Rice M
J Natl Cancer Inst; 2005 Oct; 97(19):1403-5. PubMed ID: 16204689
[No Abstract] [Full Text] [Related]
10. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Demirci E; Omes-Smit G; Zwiers A
Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
[TBL] [Abstract][Full Text] [Related]
11. Pathways to faster access to medicines.
Drug Ther Bull; 2018 Aug; 56(8):93-96. PubMed ID: 30135065
[TBL] [Abstract][Full Text] [Related]
12. Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP.
Cohen A; Bonini S
Br J Clin Pharmacol; 2018 Jul; 84(7):1399-1400. PubMed ID: 29851119
[No Abstract] [Full Text] [Related]
13. Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999-2017: Clinical efficacy considerations.
Morgan-Warren PJ
Eur J Ophthalmol; 2020 Mar; 30(2):321-349. PubMed ID: 30832499
[TBL] [Abstract][Full Text] [Related]
14. Future of the European Union regulatory network in the context of the uptake of new medicines.
Hoebert JM; Irs A; Mantel-Teeuwisse AK; Leufkens HG
Br J Clin Pharmacol; 2013 Jul; 76(1):1-6. PubMed ID: 23043328
[No Abstract] [Full Text] [Related]
15. Availability of paediatric information in European Medicines Agency approvals.
Hwang TJ; Tomasi PA; Saint-Raymond A; Bourgeois FT
Lancet Child Adolesc Health; 2018 May; 2(5):e9. PubMed ID: 30169272
[No Abstract] [Full Text] [Related]
16. European Medicines Agency: leave the UK but remain the same.
Garattini L; Curto A
J R Soc Med; 2016 Sep; 109(9):324-5. PubMed ID: 27609795
[No Abstract] [Full Text] [Related]
17. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
[No Abstract] [Full Text] [Related]
18. [Regulation about generics approval].
Laguna-Goya N; Blázquez-Pérez A; Pozo-Hernández C
Farm Hosp; 2006; 30(6):379-84. PubMed ID: 17298196
[TBL] [Abstract][Full Text] [Related]
19. Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-Sectional Analysis of Centralized Procedures in the European Union 2010-2020.
Mantila KM; Pasmooij AMG; Hallgreen CE; Mol PGM; van Boven JFM
Clin Pharmacol Ther; 2022 Nov; 112(5):1051-1060. PubMed ID: 35816103
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.
Abbasi K; Herxheimer A
BMJ; 1998 Oct; 317(7163):898. PubMed ID: 9756800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
